Abstract: Chronic neuroinflammation, a feature common to neurodegenerative diseases such as Alzheimer’s Disease, Parkinson’s Disease, and Amyotrophic Lateral Sclerosis, may be responsive to therapeutic intervention. Recent research has identified glial cells as mediators of neurodegeneration, driving disease onset and progression.
The aim of neuroscience research in this area is to acquire an in-depth understanding of the chronological events that lead to neuroinflammation, in order to promote the neuroprotective pathways.
Get a PDF version using the form:
Ncardia is an expert in human induced pluripotent stem cell (hiPSC)-technology. To overcome the limitations of primary or animal-derived cellular models regarding translatability, reproducibility and availability, they develop fully functional hiPSC-derived (disease) models and phenotypic assays for drug discovery. An example is their neuroinflammation platform which is based on combining Ncyte Astrocytes (hiPSC-derived astrocytes) and HTRF® technology.
PerkinElmer | Cisbio offers HTRF (Homogeneous Time-Resolved Fluorescence) cell-based assay kits that enable the accurate measurement of key intracellular or secreted markers, while saving precious samples thanks to their low volume consumption.
This collaborative study carried out by the two companies demonstrates that Ncyte Astrocytes combined with HTRF cellular assays represent a straightforward and physiologically relevant solution for the study of neuroinflammation pathways that are altered in various neurodegenerative disorders.